
    
      A phase III, single-group, open-label study of GSK Biologicals' vaccine BoostrixTM
      administered as a booster vaccine dose in healthy Vietnamese children aged 6-10 years. A
      single booster dose of BoostrixTM will be administered at Visit 1 (Day 0) and subjects will
      be observed until Visit 2 (Day 30). Safety will be assessed in terms of solicited adverse
      events (during 4 days post vaccination), unsolicited adverse events (during 31 days post
      vaccination) and serious adverse event (during the trial period).

      This protocol summary was updated following an administrative change of adding the EudraCT
      number to this study.
    
  